Gut Microbiota Proteins Stimulating Pancreatic Beta Cell Proliferation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Type I diabetes are inadequate, and there is a need for therapies that can increase the number of pancreatic β cells to improve insulin production and diabetes management.
Innovation Solution
Identification and use of proteins from gut microbiota, such as Aeromonas, that stimulate the proliferation, differentiation, and survival of pancreatic β cells, including recombinant vectors and nucleic acids encoding these proteins, to treat or inhibit diabetes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for Type I diabetes are used, then insulin can be administered to manage blood glucose levels, but the number of pancreatic β cells continues to decrease or is lost
Solution Approach 1:
The patent applies preliminary action by administering proteins that stimulate β cell proliferation and differentiation before complete β cell loss occurs. The proteins (such as those from gut microbiota like Aeromonas) are given proactively to expand the β cell pool in advance, preventing the eventual exhaustion of β cells that would occur with current insulin-only therapies.
Solution Approach 2:
The patent employs self-service by using proteins that activate the body's own β cells to proliferate and differentiate autonomously. Rather than providing external insulin replacement, the treatment enables the pancreatic β cells to self-renew and self-maintain through stimulation of endogenous proliferation pathways, creating a sustainable internal solution.
2Reliability
If insulin administration is used to treat Type I diabetes, then blood glucose control is achieved, but additional therapies are needed to increase β cell number
Solution Approach 1:
The patent merges two therapeutic approaches: continued insulin administration for immediate blood glucose control combined with protein therapy to increase β cell number. This combination creates a comprehensive treatment regimen that addresses both the symptomatic management (insulin replacement) and the underlying problem (β cell depletion), expanding therapeutic versatility.
Solution Approach 2:
The patent develops a multi-functional therapy where the administered proteins serve multiple functions: stimulating β cell proliferation, enhancing β cell differentiation, and potentially improving β cell survival. This single therapeutic intervention addresses multiple aspects of β cell deficiency simultaneously, providing versatile treatment that complements insulin therapy.
Data Source
AI summary
Methods of identifying compounds that increase β cell number and/or proliferation by determining the effect of compounds on β cell number or proliferation in zebrafish pancreas are provided.